Skip to main content

Advertisement

SpringerLink
Log in

Bevacizumab Treatment Before Resection of Colorectal Liver Metastases: Safety, Recovery of Liver Function, Pathologic Assesment

  • Research
  • Published:
Pathology & Oncology Research

Abstract

Patients with metastatic colorectal cancer receive chemotherapy prior liver resection more and more frequently. This preoperative treatment has many effects which have to be analysed, like the safety of liver resection, toxicity, tissue regeneration, radiological and pathological response and survival data. The aim of the study was to evaluate the safety of bevacizumab containing preoperative chemotherapy and functional recovery of the liver after resection for colorectal liver metastases (CLM) and to analyse radiological and pathological data. Data of three groups of 120 consecutive patients—(1) CTX + BV: cytotoxic chemotherapy + bevacizumab, (2) CTX: cytotoxic chemotherapy, (3) NC: no treatment before liver resection—were analysed. Postoperative liver function and complications were compared, clinical, radiological and pathological data were evaluated. Between 01.12.2006 and 31.12.2010 41 resections was performed after chemotherapy + bevacizumab (CTX + BV) and 27 resections was performed after preoperative chemotherapy without bevacizumab (CTX). There were 60 hepatic resections in this period without neoadjuvant treatment (NC). 8 patients had repeated resections. The postoperative complication rate was 40 % but there was no statistical difference between the groups (P = 0.72). Only the type of resection was associated with a significantly higher complication rate (p = 0.03). The subgroup of patients, who received irinotecan had a higher complication rate in the CTX group than in the BV + CTX group (55 % vs 41 %). Preoperative administration of bevacizumab was associated with higher peak postoperative AST, ALT levels but did not affect functional recovery of the liver. The RECIST system was not able to predict the outcome after chemotherapy in every patient and in many cases this system overestimated the effect of chemotherapy. On histopathological examination the presence of necrosis was not associated with chemotherapy or pathological response. Use of chemotherapy before hepatic resection of CLM was not associated with a significant increase in complication rates. The functional recovery of the liver was not affected by the preoperative administration of chemotherapy. The use of combined neoadjuvant chemotherapy is safe before hepatic resection.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Adam R, Delvart V, Pascal G et al (2004) Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg 240:644–657

    Article  PubMed  Google Scholar 

  2. Kesmodel B, Ellis L et al (2008) Preoperative bevacizumab does not significantly increase postoperative complication rates in patients undergoing hepatic surgery for colorectal cancer liver metastases. J Clin Oncol 26(32):5224–5260

    Article  Google Scholar 

  3. Wicherts DA, de Haas RJ, Adam R et al (2011) Impact of bevacizumab on functional recovery and histology of the liver after resection of colorectal metastases. Br J Surg 98(3):399–407

    Article  PubMed  CAS  Google Scholar 

  4. Folprecht G, Gruenberger T, Bechstein WO et al (2010) Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol 11(1):38–47

    Article  PubMed  CAS  Google Scholar 

  5. Van Cutsem E, Rivera F, Berry S et al (2009) Safety and efficacy of firstline bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Ann Oncol 20(11):1842–1847

    Article  PubMed  Google Scholar 

  6. Scoggins CR, Campbell ML, Landry CS et al (2009) Preoperative chemotherapy does not increase morbidity or mortality of hepatic resection for colorectal cancer metastases. Ann Surg Oncol 16(1):35–41

    Article  PubMed  Google Scholar 

  7. Vauthey JN, Pawlik TM, Ribero D et al (2006) Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol 24(13):2065–2072

    Article  PubMed  CAS  Google Scholar 

  8. Ribero D, Wang H, Donadon M et al (2007) Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases. Cancer 110(12):2761–2767

    Article  PubMed  Google Scholar 

  9. Klinger M, Eipeldauer S, Hacker S et al (2009) Bevacizumab protects against sinusoidal obstruction syndrome and does not increase response rate in neoadjuvant XELOX/FOLFOX therapy of colorectal cancer liver metastases. Eur J Surg Oncol 35(5):515–520

    Article  PubMed  CAS  Google Scholar 

  10. D’Angelica M, Kornprat P, Gonen M et al (2007) Lack of evidence for increased operative morbidity after hepatectomy with perioperative use of bevacizumab: a matched casecontrol study. An Surg Oncol 14:759–765

    Article  Google Scholar 

  11. Ellis LM, Curley SA et al (2005) Surgical resection after downsizing of colorectal liver metastasis in the era of Bevacizumab. J Clin Oncol 23(22):4853–4855

    Article  PubMed  CAS  Google Scholar 

  12. Reddy SK, Morse MA, Hurwitz HI et al (2008) Addition of bevacizumab to irinotecan and oxaliplatin based preoperative chemotherapy regimens does not increase morbidity after resection of colorectal liver metastases. J Am Coll Surg 206:96–106

    Article  PubMed  Google Scholar 

  13. Mahfud M, Breitenstein S, El-Badry AM et al (2010) Impact of preoperative bevacizumab on complications after resection of colorectal liver metastases: case-matched control study. World J Surg 34(1):92–100

    Article  PubMed  Google Scholar 

  14. Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment is solid tumors. J Natl Cancer Inst 92:205–216

    Article  PubMed  CAS  Google Scholar 

  15. Dindo D, Demartines N, Clavien PA (2004) Classification of surgical complications a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 240:205–213

    Article  PubMed  Google Scholar 

  16. Dan G, Blazer III, Kishi Y et al (2008) Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases. J Clin Oncol 25(33):5344–5351

    Google Scholar 

  17. Nordlinger B, Vauthey J-N, Poston G et al (2010) The timing of chemotherapy and surgery for the treatment of colorectal liver metastases. Clin Colorectal Cancer 9(4):212–218

    Article  PubMed  CAS  Google Scholar 

  18. Spelt L, Andersson B, Nilsson J, Andersson R (2012) Prognostic models for outcome following liver resection for colorectal cancer metastases: a systematic review. EJSO 38:16–24

    Article  PubMed  CAS  Google Scholar 

  19. Gruenberger B, Tamandl D, Schueller J et al (2008) Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer. J Clin Oncol 26(11):1830–1835

    Article  PubMed  CAS  Google Scholar 

  20. Nordlinger B, Sorbye H, Glimelius B et al (2008) Perioperative chemotherapywith FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomisedcontrolled trial. Lancet 371(9617):1007–1016

    Article  PubMed  CAS  Google Scholar 

  21. Chua TC, Saxena A, Liauw A et al (2010) Systematic review of randomized and nonrandomized trials of the clinical response and outcomes of neoadjuvant systemic chemotherapy for resectable colorectal liver metastases. Ann Surg Oncol 17(2):492–501

    Article  PubMed  Google Scholar 

  22. Nordlinger B, Van Cutsem E, Gruenberger T, European Colorectal Metastases Treatment Group; Sixth International Colorectal Liver Metastases Workshop et al (2009) Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel. Ann Oncol 20(6):985–992

    Article  PubMed  CAS  Google Scholar 

  23. Lehmann K, Rickenbacher A, Weber A, Pestalozzi BC, Clavien PA (2012) Chemotherapy before liver resection of colorectal metastases: friend or foe? Ann Surg 255:237–247

    Article  PubMed  Google Scholar 

  24. Scappaticci FA, Fehrenbacher L, Cartwright T et al (2005) Surgical woundhealing complications in metastatic colorectal cancer patients treated with bevacizumab. J Surg Oncol 91:173–180

    Article  PubMed  CAS  Google Scholar 

  25. Tamandl D, Gruenberger B, Klinger M et al (2010) Liver resection remains a safe procedure after neoadjuvant chemotherapy including bevacizumab: a case-controlled study. Ann Surg 252(1):124–130

    Article  PubMed  Google Scholar 

  26. Kishi Y, Zorzi D, Contreras CM et al (2010) Extended preoperative chemotherapy does not improve pathologic response and increases postoperative liver insufficiency after hepatic resection for colorectal liver metastases. Ann Surg Oncol 17(11):2870–2876

    Article  PubMed  Google Scholar 

  27. Gordon MS, Margolin K, Talpaz M et al (2001) Phase I safety and pharmacokineticstudy of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 19(3):843–850

    PubMed  CAS  Google Scholar 

  28. Chun YS, Vauthey JN, Boonsirikamchai P et al (2009) Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal livermetastases. JAMA 302(21):2338–2344

    Article  PubMed  CAS  Google Scholar 

  29. Rubbia-Brandt L, Giostra E, Brezault C et al (2007) Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neoadjuvant chemotherapy followed by liver surgery. Ann Oncol 18:299–304

    Article  PubMed  CAS  Google Scholar 

  30. Dipen MM, Kopetz S, Boonsirikamchai P et al (2010) Tumor thickness at the tumor-normal interface: a novel pathologic indicator of chemotherapy response in hepatic colorectal metastases. Am J Surg Pathol 34:1287–1294

    Article  Google Scholar 

  31. Li Chang HH, Leeper WR, Chan G, Quan D, Driman DK (2012) Infarct-like necrosis. A distinct form of necrosis seen in colorectal carcinoma liver metastases treated with perioperative chemotherapy. Am J Surg Pathol 36:570–576

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery, Uzsoki Teaching Hospital, 1145, Budapest, Uzsoki utca 29, Hungary

    K. Dede, T. Mersich, I. Besznyák, F. Jakab & A. Bursics

  2. Department of Pathology, Uzsoki Teaching Hospital, Budapest, Hungary

    F. Salamon

  3. Ist. Department of Surgery, Semmelweis University, Budapest, Hungary

    A. Zaránd

  4. Department of Surgery, Szt Imre Hospital, Budapest, Hungary

    Zs. Baranyai

  5. Department of Oncology, Uzsoki Teaching Hospital, Budapest, Hungary

    L. Landherr

Authors
  1. K. Dede
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. T. Mersich
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. I. Besznyák
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A. Zaránd
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. F. Salamon
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Zs. Baranyai
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. L. Landherr
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. F. Jakab
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. A. Bursics
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to K. Dede.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Dede, K., Mersich, T., Besznyák, I. et al. Bevacizumab Treatment Before Resection of Colorectal Liver Metastases: Safety, Recovery of Liver Function, Pathologic Assesment. Pathol. Oncol. Res. 19, 501–508 (2013). https://doi.org/10.1007/s12253-013-9608-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12253-013-9608-2

Keywords

Search

Navigation